Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/8/2017 |
| Start Date: | October 25, 2017 |
| End Date: | June 30, 2019 |
| Contact: | Hanmi Pharmaceuticals |
| Email: | clinical4@hanmi.co.kr |
| Phone: | +82-2-410-9114 |
A Phase 1, Multiple Ascending Dose, Glucose Clamp Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM12460A Compared to Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2
Diabetes Mellitus.
Diabetes Mellitus.
Inclusion Criteria:
- Type 2 diabetes mellitus
- Female subjects must be non-pregnant and non-lactating
Exclusion Criteria:
- Recurrent severe hypoglycemia or hypoglycemic unawareness or recent severe
ketoacidosis, as judged by the Investigator
- Pregnant or lactating women
- Participation in an investigational study within 30 days prior to dosing
We found this trial at
1
site
Click here to add this to my saved trials
